Methods for Identifying Out-of-Trend Data in Analysis of Stability Measurements–Part I: Regression Control Chart

News
Article
Pharmaceutical TechnologyPharmaceutical Technology-11-02-2017
Volume 41
Issue 11
Pages: 46-53

In Part I of this article series, the regression control chart method for identifying out-of-trend data in pharmaceutical stability studies is investigated, and an improved approach is suggested.

kentoh/shutterstock.com

Abstract

The regulation of pharmaceutical stability studies still lacks universally accepted techniques regarding the identification of out-of-trend data. Three methods have been suggested for identifying out-of-trend data in pharmaceutical stability studies: the regression control chart, the by-time-point method, and the slope control chart. In Part I of this article series, the regression control chart method is investigated, and an improved approach is suggested. The method is illustrated using realistic data. In Part II, the by-time-point method and the multivariate control chart method will be discussed.

Click here to view a PDF of this article.

Peer-Review Article
Submitted: March 22, 2017
Accepted: June 27, 2017

About the Authors

Máté Mihalovits is a PhD student, mihalovits@mail.bme.hu; and Sándor Kemény* is an emeritus professor, Tel.: +36 309936307, kemeny@mail.bme.hu, both at Budapest University of Technology and Economics, Faculty of Chemical Technology and Biotechnology, Department of Chemical and Environmental Process Engineering Hungary, 1111. Budapest, Műegyetem rakpart 3.

* To whom all correspondence should be addressed.

Article Details

Pharmaceutical Technology
Vol. 41, No. 11
November 2017
Pages: 46–53

Citation:

When referring to this article, please cite it as M. Mihalovits and S. Kemény, "Methods for Identifying Out-of-Trend Data in Analysis of Stability Measurements–Part I: Regression Control Chart," Pharmaceutical Technology 41 (11) 2017.

Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Related Content